Zhangzhou Pientzehuang Pharmaceutical (600436) Q3 2024 earnings summary

Executive summary

• Revenue for the first nine months of 2024 reached RMB 8.45 billion, up 11.19% year-over-year.

• Net profit attributable to shareholders was RMB 2.69 billion, increasing 11.73% year-over-year.

• Basic and diluted EPS for the period were RMB 4.45, up 11.53% year-over-year.

• Cash flow from operating activities decreased by 45.41% due to higher cash outflows for raw material purchases.

Financial highlights

• Gross margin and operating profit margin remained robust, supporting double-digit net profit growth.

• Total assets at September 30, 2024, were RMB 17.99 billion, up 5.31% from year-end 2023.

• Shareholders' equity increased 4.82% to RMB 14.02 billion compared to year-end 2023.

• Net cash from operating activities for the first nine months was RMB 1.30 billion.

• Net cash from financing activities was negative RMB 1.45 billion, reflecting dividend payments and debt repayments.

Key financial ratios and metrics

• Weighted average ROE for the period was 18.92%, down 0.64 percentage points year-over-year.

• Basic and diluted EPS for Q3 were RMB 1.60, up 11.89% year-over-year.

• Net profit margin remained strong, supporting overall profitability.